Trailing Twelve Months Sales Growth: collplant.com (CLGN)

Operating within a zone of regional conflicts, CollPlant Biotechnologies successfully leverages Western partnerships. The year-over-year dynamics of core revenue over a rolling 12-month period confirm current stability, with the metric reaching -87.10. The company anticipates future success in 3D bioprinting of tissues, although a shortage of chemical components due to logistics disruptions may slow the release of new drugs.
CollPlant Biotechnologies Ltd. - analytical breakdowns and key metrics (CLGN)

Year-over-year (TTM) sales growth measures the percentage change in total revenue over the last four quarters relative to the same period last year. This metric allows for an assessment of real market demand by excluding seasonal fluctuations. By analyzing the revenue trend over four quarters versus the prior year, an investor can determine the business scaling rate. For CollPlant Biotechnologies (CLGN), this confirms the effectiveness of the commercialization of plant-based collagen. Yehiel Tal's bioprinting strategy is directly reflected in this price action.